首页 期刊 论文 学科刊群 资讯 加盟 关于
EN
image
Article(id=1322901665849934755, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322901641049015115, articleNumber=null, orderNo=null, doi=null, pmid=null, cstr=null, oa=null, hot=null, price=null, onlineType=0, articleFormat=0, articleType=null, articleTypeStr=null, receivedDate=null, receivedDateStr=null, revisedDate=null, revisedDateStr=null, acceptedDate=1611504000000, acceptedDateStr=2021-01-25, onlineDate=1793333935463, onlineDateStr=2026-10-30, pubDate=1626278400000, pubDateStr=2021-07-15, doiRegisterDate=null, doiRegisterDateStr=null, onlineIssueDate=1793333935463, onlineIssueDateStr=2026-10-30, onlineJustAcceptDate=null, onlineJustAcceptDateStr=null, onlineFirstDate=null, onlineFirstDateStr=null, sourceXml=null, magXml=null, createTime=1793333935463, creator=13701087609, updateTime=1793333935463, updator=13701087609, issue=Issue{id=1322901641049015115, tenantId=1146029695717560320, journalId=1235980733773295621, year='2021', volume='30', issue='13', pageStart='1153', pageEnd='1248', issueExtLink='null', onlineDate='null', pubDate='1626278400000', pubDateStr='2021-07-15', beforeIssueId=null, nextIssueId=null, price=null, status=1, issueComplete=1, articleOrder=1, issueType=-1, specialIssue=null, createTime=1793333929460, creator='13701087609', updateTime=1793333989426, updator='13701087609', preIssue=null, nextIssue=null, articleTotal=null, ext={EN=IssueExt(id=1322901892623376986, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322901641049015115, language=EN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=), CN=IssueExt(id=1322901892627571291, tenantId=1146029695717560320, journalId=1235980733773295621, issueId=1322901641049015115, language=CN, specialIssueTitle=, coverIllustrator=null, specialIssueEditor=, specialIssueAbout=)}, issueFiles=null, downloadFileDto=null}, startPage=1242, endPage=1248, ext={EN=ArticleExt(id=1322901667162751908, articleId=1322901665849934755, tenantId=1146029695717560320, journalId=1235980733773295621, language=EN, title=Rapid health technology assessment of ranibizumab for wet age-related macular degeneration, columnId=null, journalTitle=Chinese Journal of New Drugs, columnName=null, runingTitle=null, highlight=null, articleAbstract=
Objective:

Ranibizumab prevents the formation of new blood vessels and reduces blood vessel permeability via inhibiting vascular endothelia growth factor (VEGF). In clinical, it is mainly used to treat wet age-related macular degeneration (wAMD). In this study, the safety, effectiveness and economics of ranibizumab in the treatment of wAMD were evaluated in order to provide an evidence-based basis for clinical rational use.

Methods:

Databases were systematically searched, including Pubmed, Ovid, the Cochrane Library, CNKI, Wanfang and CMB, according to the inclusion and exclusion criteria. The literatures were screened, the data were extracted, and then qualitative analysis on the results was conducted by 2 researchers separately.

Results:

17 Meta-analyses and 27 pharmacoeconomic studies were included. The results showed that the clinical effectiveness of ranibizumab in the treatment of wAMD was similar to bevacizumab, conbercept and aflibercept. However, compared with the combination of photodynamic therapy (PDT), the single use of ranibizumab had more benefit in improving patients' vision, especially on BCVA. In terms of safety, ranibizumab is safer than bevacizumab. Ranibizumab appeared significantly more cost-effective than the usual treatments, pegaptanib and PDT, while it is not cost-effective compared with bevacizumab, aflibercept and conbercept.

Conclusion:

In the treatment of wAMD, ranibizumab has no significant advantage over other clinically available drugs in effectiveness, but higher safety than bevacizumab, and lower economical than bevacizumab, aflibercept and conbercept.

, authors=Chao LI, Yi-fang PEI, Ting LI, Tian ZHANG, Ling TAN, authorsList=Chao LI, Yi-fang PEI, Ting LI, Tian ZHANG, Ling TAN, authorCompany=null, correspAuthors=Ling TAN, authorNote=null, correspAuthorsNote=null, copyrightStatement=null, copyrightOwner=null, extLink=null, articleAbsUrl=null, sourceXml=null, magXml=null, pdfUrl=null, pdf=null, pdfFileSize=null, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=null, mapNumber=null, fund=null), CN=ArticleExt(id=1322901667909338021, articleId=1322901665849934755, tenantId=1146029695717560320, journalId=1235980733773295621, language=CN, title=雷珠单抗治疗湿性年龄相关性黄斑变性的快速卫生技术评估, columnId=1236331163573342670, journalTitle=中国新药杂志, columnName=药物安全与合理应用, runingTitle=null, highlight=null, articleAbstract=
目的：

雷珠单抗通过抑制血管内皮生长因子（VEGF）阻止新生血管的形成并降低血管通透性，临床上主要用于治疗湿性年龄相关性黄斑变性（wet age-related macular degeneration，wAMD），本文通过对雷珠单抗进行快速卫生技术评估，系统评价雷珠单抗的有效性、安全性和经济性，为临床合理用药提供循证依据。

方法：

通过系统检索Pubmed，Ovid，the Cochrane Library，CNKI，CBM和Wanfang等数据库，由2位研究者独立地根据纳入排除标准进行文献筛选、质量评价及数据提取，并对数据结果进行分析。

结果：

共纳入17篇系统评价/Meta分析和27篇经济学研究。结果显示，应用雷珠单抗治疗wAMD时，其临床疗效与贝伐单抗、康柏西普及阿柏西普相当，并没有明显的优势，但单用雷珠单抗比其与光动力疗法（PDT）联合治疗时对患者的视力改善更加明显，尤其对最佳矫正视力（BCVA）的改善较为显著。安全性方面，雷珠单抗较贝伐单抗不良反应发生率更低。经济学方面，雷珠单抗与哌加他尼钠、常规治疗、PDT疗法相比，具有明显的经济性，而与贝伐单抗、阿柏西普、康柏西普相比，雷珠单抗没有经济性。

结论：

在治疗wAMD时，雷珠单抗有效性与临床现有药物相比没有显著优势，安全性较贝伐单抗高，经济性较贝伐单抗、阿柏西普、康柏西普差。

, authors=李超, 裴艺芳, 李婷, 张田, 谭玲, authorsList=李超, 裴艺芳, 李婷, 张田, 谭玲, authorCompany=null, correspAuthors=谭玲, authorNote=

李超，女，博士研究生，主要从事循证药学、药物经济学研究。联系电话：（010）85133922，E-mail：。

, correspAuthorsNote=
谭玲，女，主任药师，主要从事医院药学研究。联系电话：（010）85133923，E-mail：。
, copyrightStatement=null, copyrightOwner=《中国新药杂志》有限公司, extLink=null, articleAbsUrl=null, sourceXml=OyVyODQLeNEKKIyPvA1uUg==, magXml=LZuFmcKcktUWSq4THjA7Ow==, pdfUrl=null, pdf=PWH2gYt6FUfWeP0/ZcsBPA==, pdfFileSize=1032815, pdfExtLink=null, richHtmlUrl=null, mobilePdfUrl=null, reviewReport=null, pdfFirstPage=null, abstractGraph=null, abstractGraphContent=null, abstractVideo=null, citation=null, cebUrl=null, magXmlContent=G2ZWtfwafcouFyf8icUueg==, mapNumber=null, fund=null)}, authors=[Author(id=1322901668517512107, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=chaochao070813@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901668593009581, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901668517512107, language=EN, stringName=Chao LI, firstName=Chao, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901668668507054, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901668517512107, language=CN, stringName=李超, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio={"content":"

李超，女，博士研究生，主要从事循证药学、药物经济学研究。联系电话：（010）85133922，E-mail：。

"}, bioImg=null, bioContent=

李超，女，博士研究生，主要从事循证药学、药物经济学研究。联系电话：（010）85133922，E-mail：。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])]), Author(id=1322901668752393136, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901668844667827, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901668752393136, language=EN, stringName=Yi-fang PEI, firstName=Yi-fang, middleName=null, lastName=PEI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901668936942516, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901668752393136, language=CN, stringName=裴艺芳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])]), Author(id=1322901669108908982, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901669184406456, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901669108908982, language=EN, stringName=Ting LI, firstName=Ting, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901669251515321, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901669108908982, language=CN, stringName=李婷, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])]), Author(id=1322901669310235579, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901669608031165, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901669310235579, language=EN, stringName=Tian ZHANG, firstName=Tian, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901673148023742, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901669310235579, language=CN, stringName=张田, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])]), Author(id=1322901673227715520, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=tanling642003@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322901673345156034, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901673227715520, language=EN, stringName=Ling TAN, firstName=Ling, middleName=null, lastName=TAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901673420653507, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901673227715520, language=CN, stringName=谭玲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])])], keywords=[Keyword(id=1322901673521316804, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=EN, orderNo=1, keyword=ranibizumab), Keyword(id=1322901673781363653, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=EN, orderNo=2, keyword=wet age-related macular degeneration (wAMD)), Keyword(id=1322901673877832646, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=EN, orderNo=3, keyword=effectiveness), Keyword(id=1322901673961718727, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=EN, orderNo=4, keyword=safety), Keyword(id=1322901674062382024, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=EN, orderNo=5, keyword=economic), Keyword(id=1322901674150462409, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=CN, orderNo=1, keyword=雷珠单抗), Keyword(id=1322901674225959882, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=CN, orderNo=2, keyword=年龄相关性黄斑变性), Keyword(id=1322901675891098571, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=CN, orderNo=3, keyword=有效性), Keyword(id=1322901675958207436, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=CN, orderNo=4, keyword=安全性), Keyword(id=1322901676037899214, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, language=CN, orderNo=5, keyword=经济性)], refs=[Reference(id=1322901676339889104, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[1], rfOrder=0, authorNames=null, journalName=null, refType=null, unstructuredReference=MITCHELL P, LIEW G, GOPINATH B, et al. Age-related macular degeneration[J]. Lancet, 2018, 392(10153): 1147-1159., articleTitle=null, refAbstract=null), Reference(id=1322901676415386577, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[2], rfOrder=1, authorNames=null, journalName=null, refType=null, unstructuredReference=蒋璐, 陶继伟, 洪明胜, 等. 光动力学疗法联合雷珠单抗对比雷珠单抗治疗湿性AMD有效性和安全性的Meta分析[J]. 中华眼视光学与视觉科学杂志, 2014, 16(8): 493-499., articleTitle=null, refAbstract=null), Reference(id=1322901676482495443, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[3], rfOrder=2, authorNames=null, journalName=null, refType=null, unstructuredReference=SU YX, WU JW, GU Y. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: a systematic review and meta-analysis[J]. Photodiagnosis Photodyn Ther, 2018, 22: 263-273., articleTitle=null, refAbstract=null), Reference(id=1322901676574770132, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[4], rfOrder=3, authorNames=null, journalName=null, refType=null, unstructuredReference=SI JK, TANG K, BI HS, et al. Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials[J]. Int J Ophthalmol, 2014, 7(3): 541-549., articleTitle=null, refAbstract=null), Reference(id=1322901676658656213, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[5], rfOrder=4, authorNames=null, journalName=null, refType=null, unstructuredReference=温倩. 比较维替泊芬光动力学疗法联合雷珠单抗和雷珠单抗单用治疗湿性AMD的Meta分析[D]. 福建医科大学, 2015., articleTitle=null, refAbstract=null), Reference(id=1322901676746736598, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[6], rfOrder=5, authorNames=null, journalName=null, refType=null, unstructuredReference=BUTT T, LEE A, LEE C, et al. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes[J]. BMJ Open, 2015, 5(5): e006535., articleTitle=null, refAbstract=null), Reference(id=1322901676826428375, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[7], rfOrder=6, authorNames=null, journalName=null, refType=null, unstructuredReference=GHOSH W, WICKSTEAD R, CLAXTON L, et al. The cost-effectiveness of ranibizumab treat and extend regimen versus aflibercept in the UK[J]. Adv Ther, 2016, 33(9): 1660-1676., articleTitle=null, refAbstract=null), Reference(id=1322901680332866520, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[8], rfOrder=7, authorNames=null, journalName=null, refType=null, unstructuredReference=戴艳丽, 魏世辉. 贝伐单抗与雷珠单抗治疗年龄相关性黄斑变性全身安全性的Meta分析[J]. 中国中医眼科杂志, 2016, 26(2): 126-131., articleTitle=null, refAbstract=null), Reference(id=1322901680420946905, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[9], rfOrder=8, authorNames=null, journalName=null, refType=null, unstructuredReference=周洁, 浦锦宝, 徐柏升. 康柏西普对比雷珠单抗治疗年龄相关性黄斑变性的meta分析[J]. 中国现代应用药学, 2019, 36(14): 1819-1825., articleTitle=null, refAbstract=null), Reference(id=1322901680483861466, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[10], rfOrder=9, authorNames=null, journalName=null, refType=null, unstructuredReference=杜宇翔, 郭大东, 司俊康, 等. 贝伐单抗和雷珠单抗治疗渗出型老年性黄斑变性有效性meta分析[J]. 中华眼底病杂志, 2014, 30(3): 304-307., articleTitle=null, refAbstract=null), Reference(id=1322901680559358939, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[11], rfOrder=10, authorNames=null, journalName=null, refType=null, unstructuredReference=UETA T, NODA Y, TOYAMA T, et al. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials[J]. Ophthalmology, 2014, 121(11): 2193-2203., articleTitle=null, refAbstract=null), Reference(id=1322901680626467804, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[12], rfOrder=11, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG W, ZHANG X. Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis[J]. PLoS One, 2014, 9(10): e109744., articleTitle=null, refAbstract=null), Reference(id=1322901680689382365, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[13], rfOrder=12, authorNames=null, journalName=null, refType=null, unstructuredReference=ZHANG Y, CHIORESO C, SCHWEIZER ML, et al. Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies[J]. Invest Ophthalmol Vis Sci, 2017, 58(13): 5616-5627., articleTitle=null, refAbstract=null), Reference(id=1322901680756491230, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[15], rfOrder=13, authorNames=null, journalName=null, refType=null, unstructuredReference=CUI CM, LU H. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis[J]. Clin Interv Aging, 2018, 13: 51-62., articleTitle=null, refAbstract=null), Reference(id=1322901680848765919, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[16], rfOrder=14, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG L, ZHANG C, HUA R. Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis[J]. Expert Rev Clin Pharmacol, 2018, 12: 3625-3633., articleTitle=null, refAbstract=null), Reference(id=1322901680915874784, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[17], rfOrder=15, authorNames=null, journalName=null, refType=null, unstructuredReference=CHEN G, LI W, TZEKOV R, et al. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials[J]. Retina, 2015, 35(2): 187-193., articleTitle=null, refAbstract=null), Reference(id=1322901680987177953, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[18], rfOrder=16, authorNames=null, journalName=null, refType=null, unstructuredReference=WANG WJ, CHEN J, ZHANG XL, et al. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis[J]. Int J Ophthalmol, 2015, 8(1): 138-147., articleTitle=null, refAbstract=null), Reference(id=1322901681050092514, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[19], rfOrder=17, authorNames=null, journalName=null, refType=null, unstructuredReference=KODJIKIAN L, DECULLIER E, SOUIED EH, et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2014, 252(10): 1529-1537., articleTitle=null, refAbstract=null), Reference(id=1322901681276584931, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[20], rfOrder=18, authorNames=null, journalName=null, refType=null, unstructuredReference=NGUYEN CL, OH LJ, WONG E, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials[J]. BMC Ophthalmol, 2018, 18(1): 130., articleTitle=null, refAbstract=null), Reference(id=1322901681343693796, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[21], rfOrder=19, authorNames=null, journalName=null, refType=null, unstructuredReference=NEUBAUER AS, HOLZ FG, SCHRADER W, et al. Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration[J]. Klin Monbl Augenheilkd, 2007, 224(9): 727-732., articleTitle=null, refAbstract=null), Reference(id=1322901681406608357, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[22], rfOrder=20, authorNames=null, journalName=null, refType=null, unstructuredReference=COHEN SY, BREMOND-GIGNAC D, QUENTEL G, et al. Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(11): 1527-1534., articleTitle=null, refAbstract=null), Reference(id=1322901681498883046, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[23], rfOrder=21, authorNames=null, journalName=null, refType=null, unstructuredReference=COLQUITT JL, JONES J, TAN SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation[J]. Health Technol Assess, 2008, 12(16): iii-iv, ix-201., articleTitle=null, refAbstract=null), Reference(id=1322901681700209639, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[24], rfOrder=22, authorNames=null, journalName=null, refType=null, unstructuredReference=HERNANDEZ-PASTOR LJ, ORTEGA A, GARCIA-LAYANA A, et al. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration[J]. Clin Ther, 2008, 30(12): 2436-2451., articleTitle=null, refAbstract=null), Reference(id=1322901681796678632, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[25], rfOrder=23, authorNames=null, journalName=null, refType=null, unstructuredReference=GOWER EW, CASSARD SD, BASS EB, et al. A cost-effectiveness analysis of three treatments for age-related macular degeneration[J]. Retina, 2010, 30(2): 212-221., articleTitle=null, refAbstract=null), Reference(id=1322901682115445737, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[26], rfOrder=24, authorNames=null, journalName=null, refType=null, unstructuredReference=HERNANDEZ-PASTOR LJ, ORTEGA A, GARCIA-LAYANA A, et al. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration[J]. Graefes Arch Clin Exp Ophthalmol, 2010, 248(4): 467-476., articleTitle=null, refAbstract=null), Reference(id=1322901682190943210, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[27], rfOrder=25, authorNames=null, journalName=null, refType=null, unstructuredReference=NEUBAUER AS, HOLZ FG, SAUER S, et al. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system[J]. Clin Ther, 2010, 32(7): 1343-1356., articleTitle=null, refAbstract=null), Reference(id=1322901682266440683, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[28], rfOrder=26, authorNames=null, journalName=null, refType=null, unstructuredReference=YANAGI Y, AIHARA Y, FUKUDA T, et al. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese][J]. Nippon Ganka Gakkai Zasshi, 2011, 115(9): 825-831., articleTitle=null, refAbstract=null), Reference(id=1322901682329355244, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[29], rfOrder=27, authorNames=null, journalName=null, refType=null, unstructuredReference=ATHANASAKIS K, FRAGOULAKIS V, TSIANTOU V, et al. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece[J]. Clin Ther, 2012, 34(2): 446-456., articleTitle=null, refAbstract=null), Reference(id=1322901682534876142, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[30], rfOrder=28, authorNames=null, journalName=null, refType=null, unstructuredReference=JACKSON TL, KIRKPATRICK L, TANG G, et al. Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF monotherapy for the management of neovascular age-related macular degeneration[J]. Eye (Lond), 2012, 26(4): 557-563., articleTitle=null, refAbstract=null), Reference(id=1322901682631345136, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[31], rfOrder=29, authorNames=null, journalName=null, refType=null, unstructuredReference=PATEL JJ, MENDES MA, BOUNTHAVONG M, et al. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model[J]. J Eval Clin Pract, 2012, 18(2): 247-255., articleTitle=null, refAbstract=null), Reference(id=1322901682715231217, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[32], rfOrder=30, authorNames=null, journalName=null, refType=null, unstructuredReference=STEIN JD, NEWMAN-CASEY PA, MRINALINI T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis)[J]. Trans Am Ophthalmol Soc, 2013, 111: 56-69., articleTitle=null, refAbstract=null), Reference(id=1322901682954306546, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[33], rfOrder=31, authorNames=null, journalName=null, refType=null, unstructuredReference=STUDNICKA J, RIHOVA B, RENCOVA E, et al. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice[J]. Ophthalmologica, 2013, 230(1): 34-42., articleTitle=null, refAbstract=null), Reference(id=1322901683025609715, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[34], rfOrder=32, authorNames=null, journalName=null, refType=null, unstructuredReference=DAKIN HA, WORDSWORTH S, ROGERS CA, et al. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial[J]. BMJ Open, 2014, 4(7): e005094., articleTitle=null, refAbstract=null), Reference(id=1322901683117884406, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[35], rfOrder=33, authorNames=null, journalName=null, refType=null, unstructuredReference=ELSHOUT M, VAN DER REIS MI, WEBERS CA, et al. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252(12): 1911-1920., articleTitle=null, refAbstract=null), Reference(id=1322901683184993271, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[36], rfOrder=34, authorNames=null, journalName=null, refType=null, unstructuredReference=李洪超, 黎晓新, 谢锋. 贝伐单克隆抗体与雷珠单克隆抗体治疗新生血管性年龄相关性黄斑变性的经济学评价[J]. 中华眼科杂志, 2014(6): 426-433., articleTitle=null, refAbstract=null), Reference(id=1322901684808188920, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[37], rfOrder=35, authorNames=null, journalName=null, refType=null, unstructuredReference=PANCHMATIA HR, CLEMENTS KM, HULBERT E, et al. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden[J]. J Ophthalmol, 2016, 94(5): 441-448., articleTitle=null, refAbstract=null), Reference(id=1322901684879492089, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[38], rfOrder=36, authorNames=null, journalName=null, refType=null, unstructuredReference=VOTTONEN P, KANKAANPAA E. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model[J]. Acta Ophthalmol, 2016, 94(7): 652-656., articleTitle=null, refAbstract=null), Reference(id=1322901685022098426, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[39], rfOrder=37, authorNames=null, journalName=null, refType=null, unstructuredReference=WU B, LI J, LIN H, et al. Different strategies for the treatment of age-related macular degeneration in China: an economic evaluation[J]. J Ophthalmol, 2016, 2016: 7689862., articleTitle=null, refAbstract=null), Reference(id=1322901685181481979, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[40], rfOrder=38, authorNames=null, journalName=null, refType=null, unstructuredReference=YANAGI Y, FUKUDA A, BARZEY V, et al. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan[J]. J Med Econ, 2017, 20(2): 204-212., articleTitle=null, refAbstract=null), Reference(id=1322901685277950972, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[41], rfOrder=39, authorNames=null, journalName=null, refType=null, unstructuredReference=HERNANDEZ L, LANITIS T, CELE C, et al. Intravitreal aflibercept versus ranibizumab for wet age-related macular degeneration: a cost-effectiveness analysis[J]. J Manag Care Spec Pharm, 2018, 24(7): 608-616., articleTitle=null, refAbstract=null), Reference(id=1322901685349254141, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[42], rfOrder=40, authorNames=null, journalName=null, refType=null, unstructuredReference=VAN ASTEN F, MICHELS CTJ, HOYNG CB, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration——a cost-effectiveness analysis from a societal perspective[J]. PLoS One, 2018, 13(5): e0197670., articleTitle=null, refAbstract=null), Reference(id=1322901685416363006, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[43], rfOrder=41, authorNames=null, journalName=null, refType=null, unstructuredReference=马爱霞, 张籍元. 康柏西普对比雷珠单抗治疗老年黄斑变性的药物经济学评价[J]. 中国药物经济学, 2018, 13(9): 13: 27-31., articleTitle=null, refAbstract=null), Reference(id=1322901685558969343, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[44], rfOrder=42, authorNames=null, journalName=null, refType=null, unstructuredReference=CARRASCO J, PIETSCH GA, NICOLAS MP, et al. Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies[J]. Adv Ther, 2020, 37(1): 300-315., articleTitle=null, refAbstract=null), Reference(id=1322901685630272512, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, doi=null, pmid=null, pmcid=null, year=null, volume=null, issue=null, pageStart=null, pageEnd=null, url=null, language=null, rfNumber=[45], rfOrder=43, authorNames=null, journalName=null, refType=null, unstructuredReference=EL-DAHIYAT F, ELJILANY I. Cost-minimization analysis of ranibizumab versus aflibercept for treating saudi patients with visual impairment owing to age-related macular degeneration or diabetic macular edema[J]. Value Health Reg Issues, 2020, 22: 23-26., articleTitle=null, refAbstract=null)], funds=[Fund(id=1322901676184699855, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, awardId=TM19008, language=CN, fundingSource=北京医卫健康公益基金会医学科学研究基金资助项目(TM19008), fundOrder=null, country=null)], companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])], figs=null, attaches=null, journal=Journal(id=1235980159023624194, delFlag=0, nameCn=中国新药杂志, nameEn=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, issn=1003-3734, eissn=null, cn=11-2850/R, coden=ZXZHA6, periodic=3, language=CN, oaType=null, ccby=null, superviseOffice=null, ownerOffice=null, pubOffice=null, editorOffice=null, officeType=null, aims=null, clcCode=null, officeProv=null, officeCity=null, officeAddr=null, officeZip=null, officeEmail=null, officePhone=null, editDirector=null, officeDirector=null, officeDirectorPhone=null, officeStaffNum=null, officeEmpNum=null, coverPicUrl=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPrice=null, startedYear=null, abbrevIsoEn=Chinese Journal of New Drugs, journalRemark=null, publicationField=null, createdTime=1772610233314, updatedTime=1788948968376, createdBy=18614031015, updatedBy=13041195026, firstLetterCn=Z, firstLetterEn=Z, subjectCode=Medical and Pharmaceutical Sciences, subjectName=null, subjectCodeEn=Medical and Pharmaceutical Sciences, subjectNameEn=null, picCn=ohPEEN//Vz1tDT3ZBNTp4Q==, picEn=f9WK9bvTM4guTmS/iGhOMg==, jcr=null, cjcr=null, exts=[JournalExt(id=1304509780974924039, language=CN, name=中国新药杂志, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968404, updatedTime=1788948968404, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""}), JournalExt(id=1304509781025255688, language=EN, name=Chinese Journal of New Drugs, nameHistory1=null, nameHistory2=null, managedBy=, sponsoredBy=, publishedBy=, editorOffice=, officeProv=null, officeCity=null, officeAddr=, officeZip=, editDirector=, officeDirector=null, officePhone=null, coverPicUrl=null, journalRemark=, submitArticleUrl=null, websiteUrl=, createdTime=1788948968416, updatedTime=1788948968416, createdBy=13041195026, updatedBy=13041195026, submissionGuidelinesUrl=, submissionAuthorUrl=http://draft.newdrug.cn/journalx_zgxy/authorLogOn.action, submissionEditorUrl=http://draft.newdrug.cn/journalx_zgxy/editorLogOn.action, submissionReviewUrl=http://draft.newdrug.cn/journalx_zgxy/expertLogOn.action, submissionCeEditorUrl=, submissionAeEditorUrl=, option={"copyright":""})], databaseList=null, tenantJournalId=1235980733773295621, websiteList=[Website(id=1235982099191222761, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/CN, language=CN, createTime=1772610695884, createBy=18614031015, updateTime=1772610860397, updateBy=18614031015, name=中国新药杂志-中文, tplId=1146099689490845704, title=中国新药杂志, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983918629966444, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=articleTextType, value=kx, createTime=1772611129672, updateTime=1772611129672, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918604800617, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=banner, value=null, createTime=1772611129666, updateTime=1772611129666, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918655132271, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=grayFlag, value=0, createTime=1772611129678, updateTime=1772611129678, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918596412008, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611129664, updateTime=1772611129664, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918667715185, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=minRunFlag, value=0, createTime=1772611129681, updateTime=1772611129681, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918617383531, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/file/pic, createTime=1772611129669, updateTime=1772611129669, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918659326576, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=silenceFlag, value=0, createTime=1772611129679, updateTime=1772611129679, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918613189226, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_cn_619/, createTime=1772611129668, updateTime=1772611129668, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918634160749, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeColor, value=null, createTime=1772611129673, updateTime=1772611129673, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983918646743662, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099191222761, code=themeStyle, value=null, createTime=1772611129676, updateTime=1772611129676, creator=18614031015, updator=18614031015)]), Website(id=1235982099270914542, webName=null, webTitle=null, webDomain=null, webCopyrigh=null, webIpcNo=null, seoTitle=null, seoKeywords=null, seoDescription=null, tenantJournalId=null, journalId=1235980733773295621, journalNameCn=null, journalNameEn=null, grayFlag=null, tenantId=1146029695717560320, platformId=null, journalGroupId=null, journalGroupNameCn=null, journalGroupNameEn=null, type=1, domain=https://castjournals.cast.org.cn/joweb/zgxyzz/EN, language=EN, createTime=1772610695903, createBy=18614031015, updateTime=1772610875891, updateBy=18614031015, name=中国新药杂志-英文, tplId=1146101810881728533, title=Chinese Journal of New Drugs, delFlag=0, indexPage=/home, props=[WebsiteProps(id=1235983955829248630, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=articleTextType, value=kx, createTime=1772611138541, updateTime=1772611138541, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955804082803, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=banner, value=null, createTime=1772611138535, updateTime=1772611138535, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955854414457, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=grayFlag, value=0, createTime=1772611138547, updateTime=1772611138547, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955795694194, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=logo, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic?fileId=W567vm71kFC7UhK9TSU6xw==, createTime=1772611138533, updateTime=1772611138533, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955866997371, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=minRunFlag, value=0, createTime=1772611138550, updateTime=1772611138550, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955820860021, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=picServerUrl, value=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/file/pic, createTime=1772611138539, updateTime=1772611138539, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955862803066, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=silenceFlag, value=0, createTime=1772611138549, updateTime=1772611138549, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955812471412, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=staticResourcePath, value=https://castjournals.cast.org.cn/joweb/cast_kjdb_en_623/, createTime=1772611138537, updateTime=1772611138537, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955837637239, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeColor, value=null, createTime=1772611138543, updateTime=1772611138543, creator=18614031015, updator=18614031015), WebsiteProps(id=1235983955846025848, tenantId=1146029695717560320, journalId=null, journalGroupId=null, siteId=1235982099270914542, code=themeStyle, value=null, createTime=1772611138545, updateTime=1772611138545, creator=18614031015, updator=18614031015)])], journalTitle=中国新药杂志, weixinUrl=null, journalUrl=http://www.newdrug.cn/, iacademicId=null, status=1, seqNo=null, journalTitleEn=Chinese Journal of New Drugs, journalPhotoCn=ohPEEN//Vz1tDT3ZBNTp4Q==, journalPhotoEn=f9WK9bvTM4guTmS/iGhOMg==, journalFirstLetter=Z, journalRecommend=null, journalNew=null, journalCollection=null, jcrJf=null, cjcrJf=null, jcrJfStr=null, cjcrJfStr=null, submissionFirstDecision=null, sciSubjectClassification=null, casSubjectClassification=null, citeScore=null, totalCitationFrequency=null, icpCode=null, psCode=null, advertisingLicenseCode=null, copyrightInformation=null, country=null, option=, provinceCode=null, provinceName=null, collectFlag=false, interPubPlatform=, interPubPlatformUrl=null), detailUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/Y2021/V30/I13/1242, detailUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/Y2021/V30/I13/1242, pdfUrlCn=https://castjournals.cast.org.cn/joweb/zgxyzz/CN/PDF/Y2021/V30/I13/1242, pdfUrlEn=https://castjournals.cast.org.cn/joweb/zgxyzz/EN/PDF/Y2021/V30/I13/1242, aliStartDate=0, aliEndDate=0, collectionFlag=false, citedCount=null, citedUrl=null, previewStatus=0, delFlag=0, hasFullText=0, orderTime=1626278400000, fullTextJson=null, articleText=null, reference=null)
收藏切换
雷珠单抗治疗湿性年龄相关性黄斑变性的快速卫生技术评估
收藏切换
PDF下载
李超 , 裴艺芳 , 李婷 , 张田 , 谭玲
中国新药杂志 | 药物安全与合理应用 2021,30(13): 1242-1248
收起
收藏切换
中国新药杂志 |药物安全与合理应用 2021 , 30 (13) : 1242 -1248
雷珠单抗治疗湿性年龄相关性黄斑变性的快速卫生技术评估
全屏
[Author(id=1322901668517512107, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=0, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=chaochao070813@163.com, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901668593009581, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901668517512107, language=EN, stringName=Chao LI, firstName=Chao, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901668668507054, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901668517512107, language=CN, stringName=李超, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio={"content":"

李超，女，博士研究生，主要从事循证药学、药物经济学研究。联系电话：（010）85133922，E-mail：。

"}, bioImg=null, bioContent=

李超，女，博士研究生，主要从事循证药学、药物经济学研究。联系电话：（010）85133922，E-mail：。

, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])]), Author(id=1322901668752393136, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=1, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901668844667827, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901668752393136, language=EN, stringName=Yi-fang PEI, firstName=Yi-fang, middleName=null, lastName=PEI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901668936942516, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901668752393136, language=CN, stringName=裴艺芳, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])]), Author(id=1322901669108908982, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=2, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901669184406456, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901669108908982, language=EN, stringName=Ting LI, firstName=Ting, middleName=null, lastName=LI, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901669251515321, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901669108908982, language=CN, stringName=李婷, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])]), Author(id=1322901669310235579, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=3, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=null, emailSecond=null, emailThird=null, correspondingAuthor=0, authorType=1, ext={EN=AuthorExt(id=1322901669608031165, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901669310235579, language=EN, stringName=Tian ZHANG, firstName=Tian, middleName=null, lastName=ZHANG, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901673148023742, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901669310235579, language=CN, stringName=张田, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])]), Author(id=1322901673227715520, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, orderNo=4, firstName=null, middleName=null, lastName=null, nameCn=null, orcid=null, stid=null, country=null, authorPic=null, dead=0, email=tanling642003@126.com, emailSecond=null, emailThird=null, correspondingAuthor=1, authorType=1, ext={EN=AuthorExt(id=1322901673345156034, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901673227715520, language=EN, stringName=Ling TAN, firstName=Ling, middleName=null, lastName=TAN, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null), CN=AuthorExt(id=1322901673420653507, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, authorId=1322901673227715520, language=CN, stringName=谭玲, firstName=null, middleName=null, lastName=null, prefix=null, suffix=null, authorComment=null, nameInitials=null, affiliation=null, department=null, xref=null, address=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730, bio=null, bioImg=null, bioContent=null, aboutCorrespAuthor=null)}, companyList=[AuthorCompany(id=1322901668425237415, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, xref=null, ext=[AuthorCompanyExt(id=1322901668433626025, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=EN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China), AuthorCompanyExt(id=1322901668442014633, tenantId=1146029695717560320, journalId=1235980733773295621, articleId=1322901665849934755, companyId=1322901668425237415, language=CN, country=null, province=null, city=null, postcode=null, companyName=null, departmentName=null, remark=北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730)])])]
李超 , 裴艺芳, 李婷, 张田, 谭玲
作者信息
  • 北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730
通讯作者:
谭玲，女，主任药师，主要从事医院药学研究。联系电话：（010）85133923，E-mail：。
作者简介:

李超，女，博士研究生，主要从事循证药学、药物经济学研究。联系电话：（010）85133922，E-mail：。

Rapid health technology assessment of ranibizumab for wet age-related macular degeneration
Chao LI , Yi-fang PEI, Ting LI, Tian ZHANG, Ling TAN
Affiliations
  • Department of Pharmaceutical Science, Beijing Hospital, National Center of Gerontology, Institute of Geriatric Medicine, Chinese Academy of Medical Science, Beijing Key Laboratory of Assessment of Clinical Drugs Risk and Individual Application (Beijing Hospital), Beijing 100730, China
出版时间: 2021-07-15
文章导航
收藏切换
摘要
收起
目的：

雷珠单抗通过抑制血管内皮生长因子（VEGF）阻止新生血管的形成并降低血管通透性，临床上主要用于治疗湿性年龄相关性黄斑变性（wet age-related macular degeneration，wAMD），本文通过对雷珠单抗进行快速卫生技术评估，系统评价雷珠单抗的有效性、安全性和经济性，为临床合理用药提供循证依据。

方法：

通过系统检索Pubmed，Ovid，the Cochrane Library，CNKI，CBM和Wanfang等数据库，由2位研究者独立地根据纳入排除标准进行文献筛选、质量评价及数据提取，并对数据结果进行分析。

结果：

共纳入17篇系统评价/Meta分析和27篇经济学研究。结果显示，应用雷珠单抗治疗wAMD时，其临床疗效与贝伐单抗、康柏西普及阿柏西普相当，并没有明显的优势，但单用雷珠单抗比其与光动力疗法（PDT）联合治疗时对患者的视力改善更加明显，尤其对最佳矫正视力（BCVA）的改善较为显著。安全性方面，雷珠单抗较贝伐单抗不良反应发生率更低。经济学方面，雷珠单抗与哌加他尼钠、常规治疗、PDT疗法相比，具有明显的经济性，而与贝伐单抗、阿柏西普、康柏西普相比，雷珠单抗没有经济性。

结论：

在治疗wAMD时，雷珠单抗有效性与临床现有药物相比没有显著优势，安全性较贝伐单抗高，经济性较贝伐单抗、阿柏西普、康柏西普差。

雷珠单抗  /  年龄相关性黄斑变性  /  有效性  /  安全性  /  经济性
Objective:

Ranibizumab prevents the formation of new blood vessels and reduces blood vessel permeability via inhibiting vascular endothelia growth factor (VEGF). In clinical, it is mainly used to treat wet age-related macular degeneration (wAMD). In this study, the safety, effectiveness and economics of ranibizumab in the treatment of wAMD were evaluated in order to provide an evidence-based basis for clinical rational use.

Methods:

Databases were systematically searched, including Pubmed, Ovid, the Cochrane Library, CNKI, Wanfang and CMB, according to the inclusion and exclusion criteria. The literatures were screened, the data were extracted, and then qualitative analysis on the results was conducted by 2 researchers separately.

Results:

17 Meta-analyses and 27 pharmacoeconomic studies were included. The results showed that the clinical effectiveness of ranibizumab in the treatment of wAMD was similar to bevacizumab, conbercept and aflibercept. However, compared with the combination of photodynamic therapy (PDT), the single use of ranibizumab had more benefit in improving patients' vision, especially on BCVA. In terms of safety, ranibizumab is safer than bevacizumab. Ranibizumab appeared significantly more cost-effective than the usual treatments, pegaptanib and PDT, while it is not cost-effective compared with bevacizumab, aflibercept and conbercept.

Conclusion:

In the treatment of wAMD, ranibizumab has no significant advantage over other clinically available drugs in effectiveness, but higher safety than bevacizumab, and lower economical than bevacizumab, aflibercept and conbercept.

ranibizumab  /  wet age-related macular degeneration (wAMD)  /  effectiveness  /  safety  /  economic
李超, 裴艺芳, 李婷, 张田, 谭玲. 雷珠单抗治疗湿性年龄相关性黄斑变性的快速卫生技术评估. 中国新药杂志, 2021 , 30 (13) : 1242 -1248 .
Chao LI, Yi-fang PEI, Ting LI, Tian ZHANG, Ling TAN. Rapid health technology assessment of ranibizumab for wet age-related macular degeneration[J]. Chinese Journal of New Drugs, 2021 , 30 (13) : 1242 -1248 .
基金
收起
  • 北京医卫健康公益基金会医学科学研究基金资助项目(TM19008)
文献
收起
参考文献 引证文献
排序方式：
[1]
MITCHELL P, LIEW G, GOPINATH B, et al. Age-related macular degeneration[J]. Lancet, 2018, 392(10153): 1147-1159.
[2]
蒋璐, 陶继伟, 洪明胜, 等. 光动力学疗法联合雷珠单抗对比雷珠单抗治疗湿性AMD有效性和安全性的Meta分析[J]. 中华眼视光学与视觉科学杂志, 2014, 16(8): 493-499.
[3]
SU YX, WU JW, GU Y. Photodynamic therapy in combination with ranibizumab versus ranibizumab monotherapy for wet age-related macular degeneration: a systematic review and meta-analysis[J]. Photodiagnosis Photodyn Ther, 2018, 22: 263-273.
[4]
SI JK, TANG K, BI HS, et al. Combination of ranibizumab with photodynamic therapy vs ranibizumab monotherapy in the treatment of age-related macular degeneration: a systematic review and meta-analysis of randomized controlled trials[J]. Int J Ophthalmol, 2014, 7(3): 541-549.
[5]
温倩. 比较维替泊芬光动力学疗法联合雷珠单抗和雷珠单抗单用治疗湿性AMD的Meta分析[D]. 福建医科大学, 2015.
[6]
BUTT T, LEE A, LEE C, et al. The cost-effectiveness of initiating ranibizumab therapy in eyes with neovascular AMD with good vision: an economic model using real-world outcomes[J]. BMJ Open, 2015, 5(5): e006535.
[7]
GHOSH W, WICKSTEAD R, CLAXTON L, et al. The cost-effectiveness of ranibizumab treat and extend regimen versus aflibercept in the UK[J]. Adv Ther, 2016, 33(9): 1660-1676.
[8]
戴艳丽, 魏世辉. 贝伐单抗与雷珠单抗治疗年龄相关性黄斑变性全身安全性的Meta分析[J]. 中国中医眼科杂志, 2016, 26(2): 126-131.
[9]
周洁, 浦锦宝, 徐柏升. 康柏西普对比雷珠单抗治疗年龄相关性黄斑变性的meta分析[J]. 中国现代应用药学, 2019, 36(14): 1819-1825.
[10]
杜宇翔, 郭大东, 司俊康, 等. 贝伐单抗和雷珠单抗治疗渗出型老年性黄斑变性有效性meta分析[J]. 中华眼底病杂志, 2014, 30(3): 304-307.
[11]
UETA T, NODA Y, TOYAMA T, et al. Systemic vascular safety of ranibizumab for age-related macular degeneration: systematic review and meta-analysis of randomized trials[J]. Ophthalmology, 2014, 121(11): 2193-2203.
[12]
WANG W, ZHANG X. Systemic adverse events after intravitreal bevacizumab versus ranibizumab for age-related macular degeneration: a meta-analysis[J]. PLoS One, 2014, 9(10): e109744.
[13]
ZHANG Y, CHIORESO C, SCHWEIZER ML, et al. Effects of aflibercept for neovascular age-related macular degeneration: a systematic review and meta-analysis of observational comparative studies[J]. Invest Ophthalmol Vis Sci, 2017, 58(13): 5616-5627.
[15]
CUI CM, LU H. Clinical observations on the use of new anti-VEGF drug, conbercept, in age-related macular degeneration therapy: a meta-analysis[J]. Clin Interv Aging, 2018, 13: 51-62.
[16]
WANG L, ZHANG C, HUA R. Clinical effectiveness of ranibizumab and conbercept for neovascular age-related macular degeneration: a meta-analysis[J]. Expert Rev Clin Pharmacol, 2018, 12: 3625-3633.
[17]
CHEN G, LI W, TZEKOV R, et al. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials[J]. Retina, 2015, 35(2): 187-193.
[18]
WANG WJ, CHEN J, ZHANG XL, et al. Bevacizumab versus ranibizumab for neovascular age-related macular degeneration: a Meta-analysis[J]. Int J Ophthalmol, 2015, 8(1): 138-147.
[19]
KODJIKIAN L, DECULLIER E, SOUIED EH, et al. Bevacizumab and ranibizumab for neovascular age-related macular degeneration: an updated meta-analysis of randomised clinical trials[J]. Albrecht Von Graefes Arch Fur Klinische Und Exp Ophthalmol, 2014, 252(10): 1529-1537.
[20]
NGUYEN CL, OH LJ, WONG E, et al. Anti-vascular endothelial growth factor for neovascular age-related macular degeneration: a meta-analysis of randomized controlled trials[J]. BMC Ophthalmol, 2018, 18(1): 130.
[21]
NEUBAUER AS, HOLZ FG, SCHRADER W, et al. Cost-utility analysis of ranibizumab (Lucentis) in neovascular macular degeneration[J]. Klin Monbl Augenheilkd, 2007, 224(9): 727-732.
[22]
COHEN SY, BREMOND-GIGNAC D, QUENTEL G, et al. Cost-effectiveness sequential modeling of ranibizumab versus usual care in age-related macular degeneration[J]. Graefe's Arch Clin Exp Ophthalmol, 2008, 246(11): 1527-1534.
[23]
COLQUITT JL, JONES J, TAN SC, et al. Ranibizumab and pegaptanib for the treatment of age-related macular degeneration: a systematic review and economic evaluation[J]. Health Technol Assess, 2008, 12(16): iii-iv, ix-201.
[24]
HERNANDEZ-PASTOR LJ, ORTEGA A, GARCIA-LAYANA A, et al. Cost-effectiveness of ranibizumab compared with photodynamic treatment of neovascular age-related macular degeneration[J]. Clin Ther, 2008, 30(12): 2436-2451.
[25]
GOWER EW, CASSARD SD, BASS EB, et al. A cost-effectiveness analysis of three treatments for age-related macular degeneration[J]. Retina, 2010, 30(2): 212-221.
[26]
HERNANDEZ-PASTOR LJ, ORTEGA A, GARCIA-LAYANA A, et al. Cost-effectiveness of ranibizumab compared with pegaptanib in neovascular age-related macular degeneration[J]. Graefes Arch Clin Exp Ophthalmol, 2010, 248(4): 467-476.
[27]
NEUBAUER AS, HOLZ FG, SAUER S, et al. Cost-effectiveness of ranibizumab for the treatment of neovascular age-related macular degeneration in Germany: Model analysis from the perspective of Germany's statutory health insurance system[J]. Clin Ther, 2010, 32(7): 1343-1356.
[28]
YANAGI Y, AIHARA Y, FUKUDA T, et al. [Cost-effectiveness of ranibizumab, photodynamic therapy and pegaptanib sodium in the treatment of neovascular age-related macular degeneration in Japanese][J]. Nippon Ganka Gakkai Zasshi, 2011, 115(9): 825-831.
[29]
ATHANASAKIS K, FRAGOULAKIS V, TSIANTOU V, et al. Cost-effectiveness analysis of ranibizumab versus verteporfin photodynamic therapy, pegaptanib sodium, and best supportive care for the treatment of age-related macular degeneration in Greece[J]. Clin Ther, 2012, 34(2): 446-456.
[30]
JACKSON TL, KIRKPATRICK L, TANG G, et al. Cost analysis comparing adjuvant epimacular brachytherapy with anti-VEGF monotherapy for the management of neovascular age-related macular degeneration[J]. Eye (Lond), 2012, 26(4): 557-563.
[31]
PATEL JJ, MENDES MA, BOUNTHAVONG M, et al. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model[J]. J Eval Clin Pract, 2012, 18(2): 247-255.
[32]
STEIN JD, NEWMAN-CASEY PA, MRINALINI T, et al. Cost-effectiveness of bevacizumab and ranibizumab for newly diagnosed neovascular macular degeneration (an American Ophthalmological Society thesis)[J]. Trans Am Ophthalmol Soc, 2013, 111: 56-69.
[33]
STUDNICKA J, RIHOVA B, RENCOVA E, et al. Cost and effectiveness of therapy for wet age-related macular degeneration in routine clinical practice[J]. Ophthalmologica, 2013, 230(1): 34-42.
[34]
DAKIN HA, WORDSWORTH S, ROGERS CA, et al. Cost-effectiveness of ranibizumab and bevacizumab for age-related macular degeneration: 2-year findings from the IVAN randomised trial[J]. BMJ Open, 2014, 4(7): e005094.
[35]
ELSHOUT M, VAN DER REIS MI, WEBERS CA, et al. The cost-utility of aflibercept for the treatment of age-related macular degeneration compared to bevacizumab and ranibizumab and the influence of model parameters[J]. Graefes Arch Clin Exp Ophthalmol, 2014, 252(12): 1911-1920.
[36]
李洪超, 黎晓新, 谢锋. 贝伐单克隆抗体与雷珠单克隆抗体治疗新生血管性年龄相关性黄斑变性的经济学评价[J]. 中华眼科杂志, 2014(6): 426-433.
[37]
PANCHMATIA HR, CLEMENTS KM, HULBERT E, et al. Aflibercept vs. Ranibizumab: cost-effectiveness of treatment for wet age-related macular degeneration in Sweden[J]. J Ophthalmol, 2016, 94(5): 441-448.
[38]
VOTTONEN P, KANKAANPAA E. Cost-effectiveness of treating wet age-related macular degeneration at the Kuopio University Hospital in Finland based on a two-eye Markov transition model[J]. Acta Ophthalmol, 2016, 94(7): 652-656.
[39]
WU B, LI J, LIN H, et al. Different strategies for the treatment of age-related macular degeneration in China: an economic evaluation[J]. J Ophthalmol, 2016, 2016: 7689862.
[40]
YANAGI Y, FUKUDA A, BARZEY V, et al. Cost-effectiveness of intravitreal aflibercept versus other treatments for wet age-related macular degeneration in Japan[J]. J Med Econ, 2017, 20(2): 204-212.
[41]
HERNANDEZ L, LANITIS T, CELE C, et al. Intravitreal aflibercept versus ranibizumab for wet age-related macular degeneration: a cost-effectiveness analysis[J]. J Manag Care Spec Pharm, 2018, 24(7): 608-616.
[42]
VAN ASTEN F, MICHELS CTJ, HOYNG CB, et al. The cost-effectiveness of bevacizumab, ranibizumab and aflibercept for the treatment of age-related macular degeneration——a cost-effectiveness analysis from a societal perspective[J]. PLoS One, 2018, 13(5): e0197670.
[43]
马爱霞, 张籍元. 康柏西普对比雷珠单抗治疗老年黄斑变性的药物经济学评价[J]. 中国药物经济学, 2018, 13(9): 13: 27-31.
[44]
CARRASCO J, PIETSCH GA, NICOLAS MP, et al. Real-world effectiveness and real-world cost-effectiveness of intravitreal aflibercept and intravitreal ranibizumab in neovascular age-related macular degeneration: systematic review and meta-analysis of real-world studies[J]. Adv Ther, 2020, 37(1): 300-315.
[45]
EL-DAHIYAT F, ELJILANY I. Cost-minimization analysis of ranibizumab versus aflibercept for treating saudi patients with visual impairment owing to age-related macular degeneration or diabetic macular edema[J]. Value Health Reg Issues, 2020, 22: 23-26.
2021年第30卷第13期
PDF下载
10
3
引用本文
BibTeX
文章信息
  • 首发时间：2026-10-30
  • 出版时间：2021-07-15
补充材料
相关文章
文章信息
作者
出版历史
  • 录用日期：2021-01-25
基金
北京医卫健康公益基金会医学科学研究基金资助项目(TM19008)
作者信息
    北京医院药学部，国家老年医学中心，中国医学科学院老年医学研究院，北京市药物临床风险与个体化应用评价重点实验室（北京医院），北京　100730

通讯作者:

谭玲，女，主任药师，主要从事医院药学研究。联系电话：（010）85133923，E-mail：。
参考文献
分享链接
https://castjournals.cast.org.cn/joweb/zgxyzz/CN/1322901665849934755
分享至
全文二维码

扫描看全文

引用本文
BibTeX
本文的引用情况
2种不同金属材料的力学参数
科
Family		 属数
Number of
genus		 种数
Number of
species		 占总种数比例
Percentage of
total species (%)		 属
Genus		 种数
Number of
species		 占总种数比例
Percentage of total
species (%)
鹅膏菌科Amanitaceae 2 11 5.26 鹅膏菌属 Amanita 10 4.78
小菇科 Mycenaceae 2 12 5.74 丝盖伞属 Inocybe 5 2.39
多孔菌科 Polyporaceae 8 14 6.70 蜡蘑属 Laccaria 5 2.39
红菇科 Russulaceae 3 23 11.00 小皮伞属 Marasmius 6 2.87
小菇属 Mycena 11 5.26
光柄菇属 Pluteus 5 2.39
红菇属 Russula 17 8.13
栓菌属 Trametes 5 2.39
关闭全屏
相关链接
论文
最新文章
热读文章
热点专题
内参
蓝皮书
产业发展报告
传播力报告
期刊分级目录
资讯
学术新闻
行业新闻
学术会议
行业会议
关于
关于我们
联系我们
北京市海淀区学院南路86号
100081
010-62662699（运营及技术支持）
qkjq@cast.org.cn

中国科学技术协会版权所有 京ICP 备10216604号-4 海淀分局备案 1101084647
科技导报社主办 中国科协信息中心技术支持